Last reviewed · How we verify
NCT07269886: 3BD-Test
BIOMARKERS FOR DRUG SELECTION IN DEPRESSION
trial in Depression - Major Depressive Disorder in 79 participants. Completed in 30 June 2025.
16 October 2022
Quick facts
| Lead sponsor | Neomente SAS |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 79 |
| Start date | 18 August 2022 |
| Primary completion | 16 October 2022 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across Argentina |
Conditions studied
- Depression - Major Depressive Disorder — all drugs for Depression - Major Depressive Disorder →
Sponsor
Neomente SAS
Who can join
Adults 18 to 65, any sex, with Depression - Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to assess whether providing Clinical Decision Support Software (CDSS) information improves the pharmacological response in patients with depression. The CDSS integrates genomic, clinical, and blood biomarker data to assist psychiatrists in selecting the most appropriate treatment for each patient. A total of 72 patients diagnosed with Major Depressive Disorder were recruited. Participants were male and female adults aged 18 to 65 years, all presenting with moderate to severe symptomatology as assessed by the HAM-D-17 scale. Enrolled patients were randomized into two groups: * TAU group (Treatment as Usual) (+): patients received standard clinical care. * CDSS group: psychiatrists received and could incorporate CDSS-generated information when making treatment decisions. (+) The TAU group received CDSS information at the 12-week follow-up. All patients underwent blood collection at baseline (for blood-based and genomic biomarkers) and completed clinical evaluations at baseline, and at 8, 12, and 24 weeks of follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07269886
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depression - Major Depressive Disorder
Currently open trials in the same condition.
- NCT07390786 — Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot · NA · recruiting
- NCT07372586 — Behavioral Health Collaborative Care Model in an ICU Recovery Clinic · NA · recruiting
- NCT07383467 — No Time to Wait: Single Session Intervention · NA · recruiting
- NCT07026461 — Right-sided 1-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Left-sided Intermittent Theta Burst Stimulat · Phase 4 · recruiting
- NCT06793397 — A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07269886 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neomente SAS
- Last refreshed: 8 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07269886.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing